🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out our latest episode "The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma" with Manni Mohyuddin Anthony Perissinotti and Bernie Marini 🦅💨 #myeloma #badblood creators.spotify.com/pod/show/wolve…

For those who cheered too soon - an excellent analysis of the greatly misinterpreted and spurious 'OS benefit', especially when applied to the real-world setting (at least in the USA and in europe). Props to Anthony Perissinotti, Bernie Marini and Manni Mohyuddin!

Step inside from the polar vortex 🥶, grab a drink ☕️🥂, and listen to our latest episode - "Navigating a BlinatumoMAD World" 🤪 Anthony Perissinotti Bernie Marini Lydia Benitez #blinatumomab #leusm creators.spotify.com/pod/show/wolve…

Rough number of good points made in this episode about Blin(k)atumomab: 182! But the best one: we spend billions on drugs that provide minimal gains for patients and we don’t spend enough on supportive factors to close the gaps in major social determinants of health. WolverHeme

My takeaways from our Heme Reports Menin session #leusm 1. Despite promising results of Menin-i (in a very tough to treat group of AML, i.e KMT2A-r) primary and acquired resistance remains and issue and is not limited to MEN1 mutations. We need to learn more. ❓ 2.

LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML. Come listen to Bernie Marini Anthony Perissinotti Charlie Foucar and Anand Patel nerd out! #leusm #gemtuzumab #aml creators.spotify.com/pod/show/wolve…

L. F. GO Already know this episode is going to be rated Explicit….

New Podcast Alert 🚨 ‘LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML’ from WolverHeme Got my Surfside Peach Tea + Vodka (a Philly original)! Penny 🐶 and I are excited to listen poolside!

What a great episode with the interesting story of Gemtuzumab in AML! Regarding the low level MRD persistance - there’s an interesting study demonstrating that the CBFB-MYH11/RUNX1-RUNX1T1 transcripts may actually persist in residual mast cells rather than leukemic blasts. 1/3

Multicenter retrospective evaluation of treatment for high risk acute promyelocytic leukemia: Real-World Outcomes from the HERO consortium First comparison between APML4 and ATRA+ATO+GO in high risk #APL doi.org/10.1002/ajh.27… #AML #LeuSM

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini James Davis, PharmD, BCOP Victoria Nachar Anthony Perissinotti Justine Preedit creators.spotify.com/pod/show/wolve…

Excellent episode on “common sense” management of CRS with Bispecific Antibodies, especially on the controversy surrounding prophylactic tocilizumab!

Maintenance Therapy in AML: A Trailblazing Slam Dunk, or a Flagrant Fowl. Always a pleasure to hear Anthony Perissinotti Bernie Marini. What a lively and engaging debate! #HOPA2025

Check out our first VIDEO episode! 📽️ "CSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically Examined" Bernie Marini Anthony Perissinotti Tycel Phillips open.spotify.com/episode/3UaSRy…

Hot off the press: AUGMENT-101 trial results of Revumenib in R/R NPM1m AML. Congratulations to everyone who contributed to this important therapeutical advancement! A huge privillege to have our team involved and to be able to help our AML patients. ashpublications.org/blood/article/…

New🚨 EMERGENCY PODCAST 🚨 episode Blood Cancer Talks! Following recent FDA ODAC proceedings, we dissect two pivotal trials & insights from FDA/panelists: 🔸 AQUILA: Daratumumab in high-risk SMM 🔸 STARGLO: Glofitamab in R/R DLBCL share.transistor.fm/s/bb61526b A short clip on STARGLO:

🔔We had to convene an emergency meeting with David Russler-Germain, MD/PhD and Manni Mohyuddin just for this episode ‼️ "ODAC - Our Decisions Are Confusing" Anthony Perissinotti Bernie Marini creators.spotify.com/pod/show/wolve…

I really enjoyed the questions and reflections here! I add 2 of my own: Is the subgroup involved (likely drawn from academic centers) truly representative of the U.S. population? Should the rest of the world stop using drugs that have not been studied in their own countries?

Me, in my car. Well done WolverHeme